TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07843641: A Phase 2, StrateGIST Legacy Study to Provide Continued Treatment With Velzatinib to Participants With Gastrointestinal Stromal Tumors (GIST) Who Have Completed a Velzatinib Parent Study

Sponsor: GlaxoSmithKline · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 72 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07843641 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07843641 Rescue Dossier →